文献速递妇科

接受根治性放化疗的宫颈癌患者DNA损伤应答蛋白表达

Expression of DNA damage response proteins in cervical cancer patients treated with radical chemoradiotherapy.
PubMed 文献 · Gynecol Oncol · 2017-01-26

本研究对117例局部晚期宫颈癌患者治疗前标本行荧光免疫组化,评估ATM、DNA-PKcs、PARP-1、Ku70和Ku86表达与预后的关系,发现ATM和PARP-1低表达与更差的无进展生存和总生存显著相关。

要点

  • ATM低表达者5年无进展生存35% vs 高表达者58%(p=0.044)。
  • PARP-1低表达者5年无进展生存24% vs 高表达者61%(p=0.003)。
  • 多因素分析中,低ATM和PARP-1表达与更差的无进展生存和总生存显著相关。

核心结论

  • 宫颈癌DNA损伤应答蛋白表达与接受放化疗患者的结局相关,免疫组化分析可能有助于指导治疗决策。

研究设计与样本

  • 对117例局部晚期宫颈癌患者治疗前标本行荧光免疫组化,用软件分析ATM、DNA-PKcs、PARP-1、Ku70和Ku86表达,并与临床病理特征比较。

主要发现

  • 5年无进展生存:ATM低表达者35% vs 高表达者58%(p=0.044)。
  • 5年无进展生存:PARP-1低表达者24% vs 高表达者61%(p=0.003)。
  • DNA-PKcs低表达者5年无进展生存30% vs 高表达者60%(p=0.050),呈边缘显著趋势。
  • ATM和PARP-1低表达同样与更低的总生存显著相关;校正FIGO分期和肿瘤大小后,低ATM和PARP-1表达仍与更差的无进展生存和总生存显著相关。
  • 成对分析提示这些蛋白的表达水平相互关联。

临床怎么用

  • 作者认为,这些DNA损伤应答蛋白的免疫组化分析可能有助于指导此类患者的治疗决策。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The management of locally advanced cervical cancer has improved significantly with the advent of cisplatin-based chemoradiotherapy (CRT) as the primary treatment regimen. Nevertheless, a significant proportion of patients fail to respond or relapse on this treatment and have a very poor prognosis. Our goal was to determine the prognostic value of a panel of proteins involved in detection and repair of DNA damage. METHODS: We performed fluorescence immunohistochemistry, and used software analysis to assess expression of DNA damage response proteins ATM, DNA-PKcs, PARP-1, Ku70 and Ku86 in 117 pre-treatment specimens from patients with locally advanced cervical cancer. We compared expression to clinicopathologic correlates to determine prognostic significance. RESULTS: Five-year progression-free survival was significantly lower in the low expressors than in high expressors of ATM (35% vs. 58%, p=0.044) and PARP-1 (24% vs. 61%, p=0.003), and showed a trend to significance for DNA-PKcs (30% vs. 60%, p=0.050). Low expression of the same proteins also correlated significantly with lower overall survival. In multivariable analysis, adjusted for FIGO stage and tumor size, low ATM and PARP-1 expression was significantly associated with both poorer progression-free and overall survival. Pairwise analyses indicated that expression levels of these proteins were correlated. CONCLUSIONS: Expression of DNA damage response proteins in cervical cancer is associated with outcome in patients treated with CRT. Immunohistochemical analysis of these proteins may be useful in guiding treatment decisions in such patients.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Ho CK, Kornaga EN, Klimowicz AC, et al. Expression of DNA damage response proteins in cervical cancer patients treated with radical chemoradiotherapy. Gynecol Oncol. 2017. PMID: 28131528. doi:10.1016/j.ygyno.2016.12.025

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。